Cytosorbents Corp Files 8-K on Other Events

Ticker: CTSO · Form: 8-K · Filed: Aug 20, 2025 · CIK: 1175151

Cytosorbents CORP 8-K Filing Summary
FieldDetail
CompanyCytosorbents CORP (CTSO)
Form Type8-K
Filed DateAug 20, 2025
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: 8-k, filing, corporate-update

Related Tickers: CTSO

TL;DR

CYTOSORBENTS CORP (CTSO) filed an 8-K on 8/20 for events on 8/14. Check for updates.

AI Summary

Cytosorbents Corporation filed an 8-K on August 20, 2025, reporting an event that occurred on August 14, 2025. The filing pertains to 'Other Events' and 'Financial Statements and Exhibits'. The company, formerly known as MedaSorb Technologies CORP and GILDER ENTERPRISES INC, is incorporated in Delaware and headquartered in Princeton, New Jersey.

Why It Matters

This 8-K filing indicates that Cytosorbents Corporation has reported significant events or updates, which could impact investors' understanding of the company's current operations and financial status.

Risk Assessment

Risk Level: low — This filing is a routine 8-K reporting 'Other Events' and financial statements, not indicating immediate significant financial distress or major corporate changes.

Key Players & Entities

FAQ

What specific 'Other Events' are being reported by Cytosorbents Corporation in this 8-K filing?

The provided text does not detail the specific 'Other Events' but indicates they are a subject of this 8-K filing.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing occurred on August 14, 2025.

What is the filing date of this 8-K for Cytosorbents Corporation?

This 8-K filing was made on August 20, 2025.

What are the former names of Cytosorbents Corporation mentioned in the filing?

The former names of Cytosorbents Corporation mentioned are MedaSorb Technologies CORP and GILDER ENTERPRISES INC.

Where are Cytosorbents Corporation's principal executive offices located?

Cytosorbents Corporation's principal executive offices are located at 305 College Road East, Princeton, New Jersey 08540.

Filing Stats: 454 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2025-08-20 16:05:59

Key Financial Figures

Filing Documents

01

Item 8.01 Results of Operation and Financial Condition On August 20, 2025, CytoSorbents Corporation (the "Company") issued a press release announcing the outcome of its appeal to the U.S. Food and Drug Administration (the "FDA") regarding the FDA's earlier denial of the Company's De Novo Market Authorization request for DrugSorb TM -ATR. A copy of the press release is furnished herewith as Exhibit 99.1.

01

Item 9.01 Exhibits (d) Exhibits Exhibit No. Description 99.1 Press Release of the Company, dated August 20, 2025 104 Cover Page Interactive Data File (embedded with the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: August 20, 2025 CYTOSORBENTS CORPORATION By: /s/ Dr. Phillip P. Chan Name: Dr. Phillip P. Chan Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing